Imunon, Inc. Proceeds from Secured Lines of Credit
Imunon, Inc. (IMNN) reported Proceeds from Secured Lines of Credit of $100.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuredLinesOfCredit · last filed 2019-03-29
- Imunon, Inc. proceeds from secured lines of credit for fiscal 2017 was $100.00K.
| Period end | Proceeds from Secured Lines of Credit 12 month |
|---|---|
| 2017-12-31 | $100.00K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |